---

Improvement in glycemic level with saxagliptin in patients of type 2 diabetes mellitus who were previously on metformin monotherapy with uncontrolled diabetes

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Akshay Dahiwele, Dinesh K Kansal*, Dheeraj Kapoor, Parveen Sharma

Volume : 5, Issue : 2, Year : 2020

Article Page : 87-90

https://doi.org/10.18231/j.ijcaap.2020.019

Suggest article by email

Get Permission

Abstract

Introduction: Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. In this study we have tried to assess the efficacy of saxagliptin in patients of type 2 DM.
Materials and Methods: A total of 35 patients were enrolled who were on metformin monotherapy and with uncontrolled diabetes. Patients were given saxagliptin 2.5 mg once a day. Patients were followed up at 1st, 3rd and 6th month and HbA1c, FPG and 2h-PG estimation was done during the follow up period. 
Results: The mean age SD in male and female patients was 61.42 yrs 6.99 and 55.93 yrs 5.74 respectively. The mean change in value from baseline at 24 weeks was 10.7%, 16.48% and 21.63% for HbA1c, FPG and 2h-PG respectively and 20% of patient had achieved HbA1c <7> Conclusion: Saxagliptin has shown an improvement in glycemic index (HbA1c, FPG, 2h-PG) during 6 months of treatment in patients of type 2 DM.

Keywords: Saxagliptin, Uncontrolled type 2DM, Efficacy.

How to cite : Dahiwele A , Kansal D K, Kapoor D , Sharma P , Improvement in glycemic level with saxagliptin in patients of type 2 diabetes mellitus who were previously on metformin monotherapy with uncontrolled diabetes. IP Int J Compr Adv Pharmacol 2020;5(2):87-90

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.